Quelle est l'importance de la formation continue ?
La formation continue est essentielle pour maintenir des compétences à jour et garantir des soins de qualité.
Formation médicaleCompétenceÉthique médicale
#4
Comment un médecin doit-il traiter les patients vulnérables ?
Il doit faire preuve de sensibilité, respecter leur dignité et adapter les soins à leurs besoins.
Patients vulnérablesÉthique médicaleDroits des patients
#5
Quelles sont les implications de la télémédecine en déontologie ?
La télémédecine doit respecter les mêmes principes éthiques, notamment la confidentialité et le consentement.
TélémédecineConfidentialitéÉthique médicale
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Déontologie médicale : Questions médicales les plus fréquentes",
"headline": "Déontologie médicale : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Déontologie médicale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-04",
"dateModified": "2025-02-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Déontologie médicale"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Éthique clinique",
"url": "https://questionsmedicales.fr/mesh/D026690",
"about": {
"@type": "MedicalCondition",
"name": "Éthique clinique",
"code": {
"@type": "MedicalCode",
"code": "D026690",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N05.350.340.162"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Serment d'Hippocrate",
"alternateName": "Hippocratic Oath",
"url": "https://questionsmedicales.fr/mesh/D006625",
"about": {
"@type": "MedicalCondition",
"name": "Serment d'Hippocrate",
"code": {
"@type": "MedicalCode",
"code": "D006625",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "N05.350.340.162.500.500"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Déontologie médicale",
"alternateName": "Ethics, Medical",
"code": {
"@type": "MedicalCode",
"code": "D004992",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Alistair Wardrope",
"url": "https://questionsmedicales.fr/author/Alistair%20Wardrope",
"affiliation": {
"@type": "Organization",
"name": "Academic Neurology Unit, The University of Sheffield, Sheffield, UK ajwardrope1@sheffield.ac.uk."
}
},
{
"@type": "Person",
"name": "David Isaacs",
"url": "https://questionsmedicales.fr/author/David%20Isaacs",
"affiliation": {
"@type": "Organization",
"name": "Clinical Ethics Service, Sydney Children's Hospital Network, Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, Australia; Sydney Health Ethics, 92/94 Parramatta Rd, Camperdown, NSW 2050, Australia. Electronic address: davidisaacs@health.nsw.gov.au."
}
},
{
"@type": "Person",
"name": "Anne Preisz",
"url": "https://questionsmedicales.fr/author/Anne%20Preisz",
"affiliation": {
"@type": "Organization",
"name": "Clinical Ethics Service, Sydney Children's Hospital Network, Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, Australia; Sydney Health Ethics, 92/94 Parramatta Rd, Camperdown, NSW 2050, Australia."
}
},
{
"@type": "Person",
"name": "Stuart McLennan",
"url": "https://questionsmedicales.fr/author/Stuart%20McLennan",
"affiliation": {
"@type": "Organization",
"name": "Institute of History and Ethics in Medicine, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany. stuart.mclennan@tum.de."
}
},
{
"@type": "Person",
"name": "Amelia Fiske",
"url": "https://questionsmedicales.fr/author/Amelia%20Fiske",
"affiliation": {
"@type": "Organization",
"name": "Institute of History and Ethics in Medicine, Technical University of Munich, Ismaninger Straße 22, 81675, Munich, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37019248",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.neubiorev.2023.105155"
}
},
{
"@type": "ScholarlyArticle",
"name": "Real-World Outcomes of Proprotein Convertase Subtilisin Kexin-9 Inhibitor Use.",
"datePublished": "2023-05-01",
"url": "https://questionsmedicales.fr/article/36795508",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/FJC.0000000000001404"
}
},
{
"@type": "ScholarlyArticle",
"name": "Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome.",
"datePublished": "2024-07-07",
"url": "https://questionsmedicales.fr/article/38972879",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-65609-w"
}
},
{
"@type": "ScholarlyArticle",
"name": "Safety of proprotein convertase subtilisin/kexin 9 inhibitors: a systematic review and meta-analysis.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35508401",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1136/heartjnl-2021-320556"
}
},
{
"@type": "ScholarlyArticle",
"name": "Association between proprotein convertase subtilisin/kexin type 9 and subclinical cerebrovascular disease in the community.",
"datePublished": "2023-02-16",
"url": "https://questionsmedicales.fr/article/36727585",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ene.15723"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Qualité, accès, évaluation des soins de santé",
"item": "https://questionsmedicales.fr/mesh/D017530"
},
{
"@type": "ListItem",
"position": 3,
"name": "Éthique",
"item": "https://questionsmedicales.fr/mesh/D004989"
},
{
"@type": "ListItem",
"position": 4,
"name": "Déontologie",
"item": "https://questionsmedicales.fr/mesh/D004995"
},
{
"@type": "ListItem",
"position": 5,
"name": "Éthique clinique",
"item": "https://questionsmedicales.fr/mesh/D026690"
},
{
"@type": "ListItem",
"position": 6,
"name": "Déontologie médicale",
"item": "https://questionsmedicales.fr/mesh/D004992"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Déontologie médicale - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Déontologie médicale",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Droits des patients",
"headline": "Droits des patients sur Déontologie médicale",
"description": "Quels sont les droits fondamentaux des patients ?\nComment les patients peuvent-ils exprimer leurs préoccupations ?\nQuelle est l'importance de l'information dans le consentement ?\nComment la déontologie aborde-t-elle la fin de vie ?\nQuelles sont les implications de la recherche sur les droits des patients ?",
"url": "https://questionsmedicales.fr/mesh/D004992?mesh_terms=Proprotein+Convertase+9#section-droits des patients"
},
{
"@type": "MedicalWebPage",
"name": "Principes éthiques",
"headline": "Principes éthiques sur Déontologie médicale",
"description": "Quels sont les principes fondamentaux de la déontologie médicale ?\nComment la déontologie protège-t-elle les patients ?\nQuel rôle joue le consentement éclairé ?\nQu'est-ce que la bienfaisance en médecine ?\nComment la déontologie aborde-t-elle les conflits d'intérêts ?",
"url": "https://questionsmedicales.fr/mesh/D004992?mesh_terms=Proprotein+Convertase+9#section-principes éthiques"
},
{
"@type": "MedicalWebPage",
"name": "Éthique de la recherche",
"headline": "Éthique de la recherche sur Déontologie médicale",
"description": "Quels sont les principes éthiques en recherche médicale ?\nComment garantir la sécurité des participants à la recherche ?\nQu'est-ce que le comité d'éthique ?\nPourquoi est-il important de publier les résultats de recherche ?\nComment gérer les conflits d'intérêts en recherche ?",
"url": "https://questionsmedicales.fr/mesh/D004992?mesh_terms=Proprotein+Convertase+9#section-éthique de la recherche"
},
{
"@type": "MedicalWebPage",
"name": "Responsabilités des médecins",
"headline": "Responsabilités des médecins sur Déontologie médicale",
"description": "Quelles sont les responsabilités d'un médecin envers ses patients ?\nComment un médecin doit-il gérer les erreurs médicales ?\nQuelle est l'importance de la formation continue ?\nComment un médecin doit-il traiter les patients vulnérables ?\nQuelles sont les implications de la télémédecine en déontologie ?",
"url": "https://questionsmedicales.fr/mesh/D004992?mesh_terms=Proprotein+Convertase+9#section-responsabilités des médecins"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Quels sont les droits fondamentaux des patients ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les droits incluent le droit à l'information, à la confidentialité et à un consentement éclairé."
}
},
{
"@type": "Question",
"name": "Comment les patients peuvent-ils exprimer leurs préoccupations ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent le faire par le biais de plaintes formelles, de discussions avec le médecin ou via des médiateurs."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'information dans le consentement ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'information permet aux patients de prendre des décisions éclairées concernant leur traitement."
}
},
{
"@type": "Question",
"name": "Comment la déontologie aborde-t-elle la fin de vie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle prône le respect des souhaits du patient, y compris les directives anticipées et les soins palliatifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les implications de la recherche sur les droits des patients ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La recherche doit respecter les droits des participants, y compris le consentement et la confidentialité."
}
},
{
"@type": "Question",
"name": "Quels sont les principes fondamentaux de la déontologie médicale ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principes incluent le respect de l'autonomie, la bienfaisance, la non-malfaisance et la justice."
}
},
{
"@type": "Question",
"name": "Comment la déontologie protège-t-elle les patients ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle garantit le respect des droits des patients et la confidentialité des informations médicales."
}
},
{
"@type": "Question",
"name": "Quel rôle joue le consentement éclairé ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le consentement éclairé est essentiel pour respecter l'autonomie du patient avant tout traitement."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que la bienfaisance en médecine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "La bienfaisance implique d'agir dans l'intérêt du patient et de promouvoir son bien-être."
}
},
{
"@type": "Question",
"name": "Comment la déontologie aborde-t-elle les conflits d'intérêts ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle exige la transparence et la divulgation des conflits d'intérêts pour protéger les patients."
}
},
{
"@type": "Question",
"name": "Quels sont les principes éthiques en recherche médicale ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les principes incluent le respect des personnes, la bienfaisance, la non-malfaisance et la justice."
}
},
{
"@type": "Question",
"name": "Comment garantir la sécurité des participants à la recherche ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel d'évaluer les risques, d'obtenir un consentement éclairé et de surveiller les effets."
}
},
{
"@type": "Question",
"name": "Qu'est-ce que le comité d'éthique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "C'est un groupe qui évalue les protocoles de recherche pour s'assurer qu'ils respectent les normes éthiques."
}
},
{
"@type": "Question",
"name": "Pourquoi est-il important de publier les résultats de recherche ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "La publication favorise la transparence, le partage des connaissances et l'amélioration des pratiques médicales."
}
},
{
"@type": "Question",
"name": "Comment gérer les conflits d'intérêts en recherche ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est crucial de déclarer tout conflit d'intérêts et de s'assurer qu'il n'influence pas les résultats."
}
},
{
"@type": "Question",
"name": "Quelles sont les responsabilités d'un médecin envers ses patients ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un médecin doit fournir des soins compétents, respecter la dignité et informer le patient."
}
},
{
"@type": "Question",
"name": "Comment un médecin doit-il gérer les erreurs médicales ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il doit les reconnaître, en informer le patient et prendre des mesures pour éviter leur répétition."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de la formation continue ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La formation continue est essentielle pour maintenir des compétences à jour et garantir des soins de qualité."
}
},
{
"@type": "Question",
"name": "Comment un médecin doit-il traiter les patients vulnérables ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il doit faire preuve de sensibilité, respecter leur dignité et adapter les soins à leurs besoins."
}
},
{
"@type": "Question",
"name": "Quelles sont les implications de la télémédecine en déontologie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La télémédecine doit respecter les mêmes principes éthiques, notamment la confidentialité et le consentement."
}
}
]
}
]
}
Clinical Ethics Service, Sydney Children's Hospital Network, Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, Australia; Sydney Health Ethics, 92/94 Parramatta Rd, Camperdown, NSW 2050, Australia. Electronic address: davidisaacs@health.nsw.gov.au.
Clinical Ethics Service, Sydney Children's Hospital Network, Children's Hospital at Westmead and Sydney Children's Hospital, Randwick, Australia; Sydney Health Ethics, 92/94 Parramatta Rd, Camperdown, NSW 2050, Australia.
The State Budget Institution of the Republic of Dagestan "The Republican Clinical Hospital - the Center of Specialized Emergency Medical Care", 367000, Makhachkala, he Republic of Dagestan, Russia.
The gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its protein product have been widely studied for their role in cholesterol and lipid metabolism. PCSK9 increases the rate of...
Although the proprotein convertase subtilisin kexin-9 inhibitors (PCSK9i) were shown to significantly lower low-density lipoprotein and reduce atherosclerotic cardiovascular disease events in clinical...
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme rel...
To determine the harms of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in people who need lipid-lowering therapy....
This systematic review included randomised controlled trials that compared PCSK9 inhibitors with placebo, standard care or active lipid-lowering comparators in people who need lipid-lowering therapy w...
We included 32 trials with 65 861 participants (with the median follow-up duration of 40 weeks, ranging from 24 to 146 weeks). The meta-analysis showed an incidence of injection-site reaction leading ...
PCSK9 inhibitors slightly increase the risk of severe injection-site reaction but not cataracts, gastrointestinal haemorrhage, neurocognitive events, new-onset diabetes or severe myalgia or muscular p...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a new target for reducing low-density lipoprotein cholesterol and incident cardiovascular disease, including stroke. However, the clinical rele...
In community-dwelling Japanese men (n = 526) aged 46-82 years without a history of cardiovascular disease, the associations of serum PCSK9 levels with the prevalence of CSVD and ICAS were assessed usi...
The median (interquartile range) age at baseline and serum PCSK9 levels were 69 (63-74) years and 240 (205-291) ng/ml, respectively. After adjusting for traditional cardiovascular risk factors includi...
Higher circulating PCSK9 levels were independently associated with an ICAS prevalence but not with CSVD prevalence. The quantification of circulating PCSK9 levels may help to identify individuals at h...
Proprotein convertase subtilisin/kexin type-9 (PCSK9) is a posttranslational regulator of the LDL receptor (LDLR). Recent studies have proposed a role for PCSK9 in regulating immune responses. Using R...
Guidelines advocate for intensive lipid-lowering in patients with atherosclerotic cardiovascular disease (ASCVD). In May 2020, evolocumab, a proprotein convertase subtilisin-kexin type 9 (PCSK9) inhib...
To identify barriers to prescribing PCSK9 inhibitors in hospitalised patients with ASCVD....
A retrospective 3-month, single-site, observational analysis was conducted in consecutive patients undergoing percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery. L...
Of 331 patients, 244 (73.7%) underwent PCI and 87 (26.3%) underwent CABG surgery. A lipid profile during or within 8 weeks of admission was measured for 202 (82.8%) patients undergoing PCI and 59 (67....
Prescribing of non-statin LDL-C-lowering therapies remains low in patients with ASCVD. Underprescribing of ezetimibe and suboptimal lipid testing rates are barriers to accessing subsidised PCSK9i ther...
Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) levels have been suggested as novel atherosclerotic biomarker. PCSK9 plays important roles in the pathogenesis of atherosclerosis by regulating th...
This cross-sectional analysis enrolled 401 Caucasian patients with type II diabetes mellitus (T2DM). PCSK9 levels were measured by ELISA test, arterial stiffness was estimated by measuring carotid-fem...
Patients were divided in three tertiles according to increasing value of PCSK9. From the I to the III tertiles, there was a significant increase in high sensitivity C-reactive protein (hs-CRP), fibrin...
Our study demonstrates a close association between circulating PCSK9 levels and PWV in T2DM subjects without previous CV events even after adjusting for well-known CV risk factor and pharmacological m...
Proprotein convertase subtilisin/kexin-type 9 inhibitor (PCSK9i) treatment reduces cardiovascular events when taken over a long time for secondary prevention. Data on treatment adherence are scarce an...
Baseline data and prescription patterns of all 7302 patients with PCSK9i prescriptions dispensed on the account of Austrian Social Insurances between September 2015 and December 2020 were retrieved an...
Considering the high PDC and low discontinuation rates, the majority of patients adhere to PCSK9i treatment. Hence, in a system where PCSK9i treatment is made available at virtually no costs for patie...
Proprotein convertase subtilisin/kexin type 9 (PCSK9) reduces low density lipoprotein (LDL) uptake, leading to increased plasma levels of LDL. In addition, PCSK9 has been implicated in inflammation in...